Multidrug‐resistant transporter expression does not always result in drug resistance

Chemotherapeutics used by Sasaki et al are not all standard of care for PDAC, precluding relevance for clinical practice. [...]studies should evaluate the correlation of ABCG2 expression with chemoresistance in a larger panel of cytotoxic agents used against PDAC, as well as report data on well‐known gemcitabine determinants, such as ENT1. [...]verapamil was previously found to be inactive against ABCG2. [...]chemoresistance contributes to poor prognosis in PDAC patients, and understanding the mechanisms that underlie this phenomenon will pave the way for improved therapy response.